key: cord-0863647-59qqs7d3
authors: Egilman, Alexander; Wallach, Joshua D.; Puthumana, Jeremy; Zhang, Audrey D.; Schwartz, Jason L.; Ross, Joseph S.
title: Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration
date: 2021-06-15
journal: J Gen Intern Med
DOI: 10.1007/s11606-021-06943-x
sha: 33a9159b2ff00ce64cafd5568689bc9b8a4dba90
doc_id: 863647
cord_uid: 59qqs7d3

nan

The US Food and Drug Administration (FDA) has thus far granted Emergency Use Authorization (EUA) to three vaccines for the prevention of coronavirus disease 2019 (COVID-1 9 ) , a u t h o r i z i n g u s ec o n t i n g e n t u p o n f u r t h e r evaluation-based on less evidence than required for traditional licensure. 1, 2 While these were FDA's first uses of EUA for novel vaccines, the "accelerated approval" pathway has for decades permitted FDA to approve vaccines based on limited preapproval evidence, specifically surrogate measures (e.g., antibody levels) reasonably likely to predict clinical benefit, while requiring completion of postapproval trials to verify clinical benefit. To inform future regulatory decisions, including the EUA or accelerated approval of vaccines for COVID-19 and other diseases, we evaluated all novel vaccines granted accelerated approval, characterizing the evidence from preapproval and postapproval trials, including how often postapproval studies confirmed clinical benefit.

Using FDA approval letters, we identified all novel vaccines granted accelerated approval from the pathway's inception in 1992 through 2017, allowing 3 years minimum for completion of postapproval trials. Following previously described approaches, 3, 4 we identified pivotal efficacy trials (i.e., those serving as the basis of FDA approval) and extracted trial characteristics from FDA's clinical reviews, as well as the total number of studies supporting approval and the prelicensure safety population. Next, we identified postapproval trials FDA required for accelerated approval, including ClinicalTrials.gov registrations and corresponding publications on PubMed, and extracted trial characteristics and determined study status.

For each preapproval and postapproval trial, we determined use of randomization, blinding, number of treated patients (overall and intervention group), completion rate, trial duration, duration of follow-up for serious adverse events (SAEs), type of comparator (active, placebo, or none), and primary endpoint (clinical outcome or surrogate measure). Lastly, we determined vaccine efficacy and assessed whether clinical benefit was confirmed. Fisher exact and Mann-Whitney U tests were conducted in R, version 3.4.0 (R Foundation for Statistical Computing) (2-sided P<0.05).

Between 1992 and 2017, FDA granted accelerated approval for 8 novel vaccines for seasonal influenza (n=5; 62.5%), meningococcus (n=2; 25.0%), and Haemophilus influenzae (n=1; 12.5%) based on a median of 9 (IQR, 7-19) total studies, including 1.5 (IQR, 1-3) pivotal efficacy trials and a total safety population of 4711 (IQR, 3718-10,968) participants. Overall, FDA required 15 postapproval trials, a median of 2 (IQR, 1-2.3) per vaccine. Within 3 and 6 years after approval, 13 (86.7%) and 14 (93.3%) of the postapproval trials were completed, respectively, while 1 (6.7%) remains delayed.

Most of the completed pivotal efficacy (n=18) and postapproval (n=14) trials were randomized ( (Table 2) .

Since 1992, FDA has granted 8 novel vaccines accelerated approval based on evidence from a median of 9 clinical studies, including 1-2 pivotal efficacy trials, while requiring 2 postapproval trials. Nearly 90% of FDA-required postapproval trials were completed within 3 years after approval, a higher rate than observed for drug approvals. 5 However, only 3 of the 8 vaccines had benefit confirmed by a postapproval trial using clinical outcomes. Our study was limited to FDA-required postapproval trials; other studies may have confirmed vaccine benefit. Given the ongoing pandemic, FDA's consideration of EUA or accelerated approval for COVID-19 vaccines is clearly justified. 6 Moreover, Pfizer-BioNTech's, Janssen's, and Moderna's pivotal efficacy trials each enrolled over 30,000 participants, used a clinical outcome as a primary efficacy endpoint, and demonstrated efficacy of 95%, 66%, and 94% in preventing COVID-19, respectively. These trials provide substantially more robust evidence than the studies used to support accelerated approval of vaccines by FDA, which had far smaller sample sizes and used surrogate measures. Going forward, FDA should acknowledge areas of evidentiary uncertainty associated with accelerated approval of vaccines and require completion of large, rigorously designed, and timely postapproval trials to assess long-term safety and clinical benefit. Author Contribution All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. ACE and JSR contributed to study concept and design; ACE abstracted the data; JDW validated the data and conducted the statistical analyses; all authors contributed to the analysis and interpretation of the data; ACE drafted the manuscript; all authors contributed to the critical revision of the manuscript; and JSR provided study supervision.

Funding This project was not supported by any external grants or funds. Dr. Wallach is supported by the National Institute on Alcohol †Vaccine efficacy and assessment of clinical benefit were determined only for postapproval trials with clinical outcomes as primary endpoints. Clinical benefit was assessed in relation to each trial's predefined criteria for establishing vaccine efficacy ‡FDA status as of May 4, 2021. FDA status categories for postapproval studies include pending, ongoing, delayed, terminated, submitted, fulfilled, and released §Active placebo control group ||While the FDA confirmed fulfillment of this study, the accelerated approval commitment to verify clinical benefit was not considered fulfilled and the FDA required an additional clinical endpoint study ¶Vaccine efficacy was assessed for significance versus placebo #To evaluate lot consistency, participants were randomized into 3 groups each receiving a different manufacturing lot of the vaccine. Group 1 represents all 3 of the groups Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Data Availability The datasets generated during the current study are available from the corresponding author on reasonable request.

Emergency Use Authorization for Vaccines to Prevent COVID-19: Guidance for Industry

Emergency approvals for COVID-19: evolving impact on obligations to patients in clinical care and research

Clinical trial evidence supporting FDA approval of novel therapeutic agents

Speed, evidence, and safety characteristics of vaccine approvals by the US Food and Drug Administration

Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration

Ethical and scientific considerations regarding the early approval and deployment of a COVID-19 vaccine

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.